162 research outputs found
Title page Anti-fibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor, nintedanib, in experimental models of lung fibrosis
Abstract word count: 256 Introduction word count: 61
Interleukin-17 is a negative regulator of established allergic asthma
T helper (Th)17 cells producing interleukin (IL)-17 play a role in autoimmune and allergic inflammation. Here, we show that IL-23 induces IL-17 in the lung and IL-17 is required during antigen sensitization to develop allergic asthma, as shown in IL-17Râdeficient mice. Since IL-17 expression increased further upon antigen challenge, we addressed its function in the effector phase. Most strikingly, neutralization of IL-17 augmented the allergic response in sensitized mice. Conversely, exogenous IL-17 reduced pulmonary eosinophil recruitment and bronchial hyperreactivity, demonstrating a novel regulatory role of IL-17. Mechanistically, IL-17 down modulated eosinophil-chemokine eotaxin (CCL11) and thymus- and activation-regulated chemokine/CCL17 (TARC) in lungs in vivo and ex vivo upon antigen restimulation. In vitro, IL-17 reduced TARC production in dendritic cells (DCs)âthe major source of TARCâand antigen uptake by DCs and IL-5 and IL-13 production in regional lymph nodes. Furthermore, IL-17 is regulated in an IL-4âdependent manner since mice deficient for IL-4Rα signaling showed a marked increase in IL-17 concentration with inhibited eosinophil recruitment. Therefore, endogenous IL-17 is controlled by IL-4 and has a dual role. Although it is essential during antigen sensitization to establish allergic asthma, in sensitized mice IL-17 attenuates the allergic response by inhibiting DCs and chemokine synthesis
Dominant-Negative Tumor Necrosis Factor Protects from Mycobacterium bovis Bacillus Calmette-Guérin (BCG) and Endotoxin-Induced Liver Injury without Compromising Host Immunity to BCG and Mycobacterium tuberculosis
BackgroundTumor necrosis factor (TNF) is associated with the development of inflammatory pathologies. Antibodies and soluble TNF (solTNF) receptors that neutralize excessive TNF are effective therapies for inflammatory and autoimmune diseases. However, clinical use of TNF inhibitors is associated with an increased risk of infections MethodsA novel dominant-negative (DN) strategy of selective TNF neutralization, consisting of blocking solTNF while sparing transmembrane TNF (tmTNF), was tested in mouse models of mycobacterial infection and acute liver inflammation. XENP1595, a DN-TNF biologic, was compared with etanercept, a TNF receptor 2 (TNFR2)-IgG1 Fc fusion protein that inhibits murine solTNF and tmTNF ResultsXENP1595 protected mice from acute liver inflammation induced by endotoxin challenge in Mycobacterium bovis bacillus Calmette-Guérin (BCG)-infected mice, but, in contrast to etanercept, it did not compromise host immunity to acute M. bovis BCG and Mycobacterium tuberculosis infections in terms of bacterial burden, granuloma formation, and innate immune responses ConclusionsA selective inhibitor of solTNF efficiently protected mice from acute liver inflammation yet maintained immunity to mycobacterial infections. In contrast, nonselective inhibition of solTNF and tmTNF suppressed immunity to M. bovis BCG and M. tuberculosis. Therefore, selective inhibition of solTNF by DN-TNF biologics may represent a new therapeutic strategy for the treatment of inflammatory diseases without compromising host immunit
Prominent role for T cell-derived Tumour Necrosis Factor for sustained control of Mycobacterium tuberculosis infection
Tumour Necrosis Factor (TNF) is critical for host control of M. tuberculosis, but the relative contribution of TNF from innate and adaptive immune responses during tuberculosis infection is unclear. Myeloid versus T-cell-derived TNF function in tuberculosis was investigated using cell type-specific TNF deletion. Mice deficient for TNF expression in macrophages/neutrophils displayed early, transient susceptibility to M. tuberculosis but recruited activated, TNF-producing CD4+ and CD8+ T-cells and controlled chronic infection. Strikingly, deficient TNF expression in T-cells resulted in early control but susceptibility and eventual mortality during chronic infection with increased pulmonary pathology. TNF inactivation in both myeloid and T-cells rendered mice critically susceptible to infection with a phenotype resembling complete TNF deficient mice, indicating that myeloid and T-cells are the primary TNF sources collaborating for host control of tuberculosis. Thus, while TNF from myeloid cells mediates early immune function, T-cell derived TNF is essential to sustain protection during chronic tuberculosis infection
IL-1 and IL-23 Mediate Early IL-17A Production in Pulmonary Inflammation Leading to Late Fibrosis
BACKGROUND: Idiopathic pulmonary fibrosis is a devastating as yet untreatable disease. We demonstrated recently the predominant role of the NLRP3 inflammasome activation and IL-1ÎČ expression in the establishment of pulmonary inflammation and fibrosis in mice. METHODS: The contribution of IL-23 or IL-17 in pulmonary inflammation and fibrosis was assessed using the bleomycin model in deficient mice. RESULTS: We show that bleomycin or IL-1ÎČ-induced lung injury leads to increased expression of early IL-23p19, and IL-17A or IL-17F expression. Early IL-23p19 and IL-17A, but not IL-17F, and IL-17RA signaling are required for inflammatory response to BLM as shown with gene deficient mice or mice treated with neutralizing antibodies. Using FACS analysis, we show a very early IL-17A and IL-17F expression by RORÎłt(+) γΎ T cells and to a lesser extent by CD4αÎČ(+) T cells, but not by iNKT cells, 24 hrs after BLM administration. Moreover, IL-23p19 and IL-17A expressions or IL-17RA signaling are necessary to pulmonary TGF-ÎČ1 production, collagen deposition and evolution to fibrosis. CONCLUSIONS: Our findings demonstrate the existence of an early IL-1ÎČ-IL-23-IL-17A axis leading to pulmonary inflammation and fibrosis and identify innate IL-23 and IL-17A as interesting drug targets for IL-1ÎČ driven lung pathology
NLRP6 controls pulmonary inflammation from cigarette smoke in a gut microbiota-dependent manner
Chronic obstructive pulmonary disease (COPD) is a major health issue primarily caused by cigarette smoke (CS) and characterized by breathlessness and repeated airway inflammation. NLRP6 is a cytosolic innate receptor controlling intestinal inflammation and orchestrating the colonic hostâmicrobial interface. However, its roles in the lungs remain largely unexplored. Using CS exposure models, our data show that airway inflammation is strongly impaired in Nlrp6-deficient mice with drastically fewer recruited neutrophils, a key cell subset in inflammation and COPD. We found that NLRP6 expression in lung epithelial cells is important to control airway and lung tissue inflammation in an inflammasome-dependent manner. Since gut-derived metabolites regulate NLRP6 inflammasome activation in intestinal epithelial cells, we investigated the link between NLRP6, CS-driven lung inflammation, and gut microbiota composition. We report that acute CS exposure alters gut microbiota in both wild-type (WT) and Nlrp6-deficient mice and that antibiotic treatment decreases CS-induced lung inflammation. In addition, gut microbiota transfer from dysbiotic Nlrp6-deficient mice to WT mice decreased airway lung inflammation in WT mice, highlighting an NLRP6-dependent gut-to-lung axis controlling pulmonary inflammation
Role of IL-1ÎČ in experimental cystic fibrosis upon P. aeruginosa Infection
Cystic fibrosis is associated with increased inflammatory responses to pathogen challenge. Here we revisited the role of IL-1ÎČ in lung pathology using the experimental F508del-CFTR murine model on C57BL/6 genetic background (Cftrtm1eur or d/d), on double deficient for d/d and type 1 interleukin-1 receptor (d/d X IL-1R1-/-), and antibody neutralization. At steady state, young adult d/d mice did not show any signs of spontaneous lung inflammation. However, IL-1R1 deficiency conferred partial protection to repeated P. aeruginosa endotoxins/LPS lung instillation in d/d mice, as 50% of d/d mice succumbed to inflammation, whereas all d/d x IL-1R1-/- double mutants survived with lower initial weight loss and less pulmonary collagen and mucus production, suggesting that the absence of IL-1R1 signaling is protective in d/d mice in LPS-induced lung damage. Using P. aeruginosa acute lung infection we found heightened neutrophil recruitment in d/d mice with higher epithelial damage, increased bacterial load in BALF, and augmented IL-1ÎČ and TNF-α in parenchyma as compared to WT mice. Thus, F508del-CFTR mice show enhanced IL-1ÎČ signaling in response to P. aeruginosa. IL-1ÎČ antibody neutralization had no effect on lung homeostasis in either d/d or WT mice, however P. aeruginosa induced lung inflammation and bacterial load were diminished by IL-1ÎČ antibody neutralization. In conclusion, enhanced susceptibility to P. aeruginosa in d/d mice correlates with an excessive inflammation and with increased IL-1ÎČ production and reduced bacterial clearance. Further, we show that neutralization of IL-1ÎČ in d/d mice through the double mutation d/d x IL-1R1-/- and in WT via antibody neutralization attenuates inflammation. This supports the notion that intervention in the IL-1R1/IL-1ÎČ pathway may be detrimental in CF patients
Etude des réponses immunitaires innées dans des modÚles d inflammation pulmonaire (stérile à la fumée de cigarette et infectieux à Mycobacterium tuberculosis)
Les travaux effectuĂ©s se sont focalisĂ©s sur deux pathologies pulmonaires diffĂ©rentes : la broncho-pneumopathie chronique obstructive (BPCO) et la tuberculose. Ces pathologies font partie des 10 principales causes de mortalitĂ© actuelles. Ces travaux ont permis, grĂące Ă l emploi de souris gĂ©nĂ©tiquement modifiĂ©es, de caractĂ©riser les rĂ©cepteurs et les voies de signalisation impliquĂ©s dans l inflammation pulmonaire induite par la fumĂ©e de cigarette ou par Mycobacterium tuberculosis. Nous avons observĂ© que les voies de signalisation TLR-4/MyD88 et IL-1R1/MyD88 contribue Ă la mise en place de l inflammation stĂ©rile induite par la fumĂ©e de cigarette. Le rĂŽle central de l IL-1β souligne l implication de la caspase-1 et l inflammasome dans cette inflammation. L Ă©tude de l implication des rĂ©cepteurs IL-1R1 et IL-18-R dans la rĂ©ponse Ă l infection Ă Mycobacterium tuberculosis, a rĂ©vĂ©lĂ© que la voie de signalisation IL1-R1 est une composante nĂ©cessaire au contrĂŽle de l infection. Mycobacterium tuberculosis pour survivre et persister sĂ©crĂštent des molĂ©cules anti-inflammatoires capables de moduler en faveur du bacille la rĂ©ponse inflammatoire de son hĂŽte. L Ă©tude de ces molĂ©cules nous a permis d isoler et de synthĂ©tiser des structures non peptidiques de faibles poids molĂ©culaires, les PIMs (Phosphatidyl-myo-inositol-mannosides), qui reprĂ©sentent un vĂ©ritable potentiel thĂ©rapeutique anti-inflammatoire.ORLEANS-BU Sciences (452342104) / SudocSudocFranceF
Implication des voies de signalisation Toll (TLR) dans la réponse immunitaire aux mycobactéries
Dans le cadre de la recherche de nouvelles molécules permettant une meilleure vaccination des individus contre la tuberculose, mon étude consiste à mieux comprendre les voies de signalisation cellulaires dans la reconnaissance hÎte-pathogÚne par l'analyse de la mise en place des réponses immunitaires innée et acquise dans des modÚles murins déficients pour les récepteurs TLR impliqués dans la reconnaissance des mycobactéries (TLR2, TLR4, TLR6) ou la molécule adaptatrice MyD88 infectés par M.bovis BCG. Des études in vitro sur les cellules dérivées des souris déficientes ont mis en évidence les effets agonistes ou antagonistes de certains composants moléculaires de la paroi du BCG pour les différents TLR. Les études in vivo, d'autre part, ont montré que la déficience en TLR2 ou TLR6 n'entraßne pas de phénotype majeur de la réponse immunitaire à l'infection à M.bovis BCG. En revanche, l'absence de voie de signalisation MyD88 induit un défaut du contrÎle de l'infection, avec une inflammation pulmonaire exacerbée.ORLEANS-BU Sciences (452342104) / SudocSudocFranceF
- âŠ